Pyoderma gangrenosum: A review and update on new therapies

Journal of the American Academy of Dermatology

Volumn 62, Issue 4, 2010, Pages 646-654

  Miller, Jeremiah ^a   Yentzer, Brad A ^a   Clark, Adele ^a   Jorizzo, Joseph L ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

adalimumab; alefacept; clinical trials; efalizumab; etanercept; infliximab

Indexed keywords

ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; CHLORAMBUCIL; CHLORMETHINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; EFALIZUMAB; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; TACROLIMUS; THALIDOMIDE;

ACUTE KIDNEY TUBULE NECROSIS; ADRENAL INSUFFICIENCY; AGRANULOCYTOSIS; ALOPECIA; ANEMIA; APHERESIS; ASEPTIC MENINGITIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRADYCARDIA; CACOGEUSIA; CATARACT; CLINICAL TRIAL; COMA; CONGESTIVE HEART FAILURE; CONSTIPATION; CROHN DISEASE; DELIRIUM; DEMYELINATING DISEASE; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ECCHYMOSIS; EDEMA; EXFOLIATIVE DERMATITIS; GLAUCOMA; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INFECTION; INFERTILITY; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MENTAL DISEASE; METHEMOGLOBINEMIA; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OSTEOPOROSIS; PANCYTOPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PYODERMA GANGRENOSUM; RASH; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN PAIN; TASTE DISORDER; TERATOGENESIS; THROMBOCYTOPENIA; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; TUBERCULOSIS; URINARY TRACT INFECTION; VERTIGO; VOMITING; WOUND CARE;

CLINICAL TRIALS AS TOPIC; HUMANS; PYODERMA GANGRENOSUM;

EID: 77749264527     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.05.030     Document Type: Review

References (63)

1. Powell F.C., Su W.P., and Perry H.O. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 34 (1996) 395-409
2. Bennett M.L., Jackson J.M., Jorizzo J.L., Fleischer Jr. A.B., White W.L., and Callen J.P. Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission; case review of 86 patients from 2 institutions. Medicine (Baltimore) 79 (2000) 37-46
3. Odom R.B., James W.D., and Berger T.G. Andrews' diseases of the skin: clinical dermatology (2000), WB Saunders Co, Philadelphia p. 158-60
4. Cummins D.L., Anhalt G.J., Monahan T., and Meyerle J.H. Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol 157 (2007) 1235-1239
5. Poritz L.S., Lebo M.A., Bobb A.D., Ardell C.M., and Koltun W.A. Management of peristomal pyoderma gangrenosum. J Am Coll Surg 206 (2008) 311-315
6. Fonder M.A., Lazarus G.S., Cowan D.A., Ronson-Cook B., Kohli A.R., and Mamelak A.J. Treating the chronic wound: a practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol 58 (2008) 185-206
7. Wollina U. Pyoderma gangrenosum-a review. Orphanet J Rare Dis 2 (2007) 19
8. Dunwoody C.J., McCann S.A., and Zumbo M. Pyoderma gangrenosum: a case study for pain management in dermatology nursing. Dermatol Nurs 12 (2000) 313-314
9. von den D.P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 137 (1997) 1000-1005
10. Piccirillo A., and Ricciuti F. Topical tacrolimus for pyoderma gangrenosum: another report. J Dermatol 33 (2006) 232
11. Bellini V., Simonetti S., and Lisi P. Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%. J Eur Acad Dermatol Venereol 22 (2008) 113-115
12. Ghislain P.D., De Decker I., and Lachapelle J.M. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. Br J Dermatol 150 (2004) 1052-1053
13. Pitarch G., Torrijos A., Mahiques L., Sanchez-Carazo J.L., and Fortea J.M. Systemic absorption of topical tacrolimus in pyoderma gangrenosum. Acta Derm Venereol 86 (2006) 64-65
14. Wenzel J., Gerdsen R., Phillipp-Dormston W., Bieber T., and Uerlich M. Topical treatment of pyoderma gangrenosum. Dermatology 205 (2002) 221-223
15. Tamir A., Landau M., and Brenner S. Topical treatment with 1% sodium cromoglycate in pyoderma gangrenosum. Dermatology 192 (1996) 252-254
16. Massone L., Borghi S., Pestarino A., and Gambini C. Topical disodium cromoglycate in the management of pyoderma gangrenosum. Cutis 42 (1988) 459-462
17. Sanders C.J., and Hulsmans R.F. Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. Cutis 51 (1993) 262-264
18. Tsele E., Yu R.C., and Chu A.C. Pyoderma gangrenosum-response to topical nitrogen mustard. Clin Exp Dermatol 17 (1992) 437-440
19. Oberyszyn T.M. Non-melanoma skin cancer: importance of gender, immunosuppressive status and vitamin D. Cancer Lett 261 (2008) 127-136
20. Brooklyn T.N., Dunnill M.G., Shetty A., Bowden J.J., Williams J.D., Griffiths C.E., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut 55 (2006) 505-509
21. Kerns M.J., Graves J.E., Smith D.I., and Heffernan M.P. Off-label uses of biologic agents in dermatology: a 2006 update. Semin Cutan Med Surg 25 (2006) 226-240
22. Roy D.B., Conte E.T., and Cohen D.J. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol 54 Suppl (2006) S128-S134
23. Pastor N., Betlloch I., Pascual J.C., Blanes M., Banuls J., and Silvestre J.F. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept). Clin Exp Dermatol 31 (2006) 152-153
24. McGowan J.W., Johnson C.A., and Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 3 (2004) 441-444
25. Goldenberg G., and Jorizzo J.L. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatolog Treat 16 (2005) 347-349
26. Charles C.A., Leon A., Banta M.R., and Kirsner R.S. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol 46 (2007) 1095-1099
27. Jacob S.E., Weisman R.S., and Kerdel F.A. Pyoderma gangrenosum-rebel without a cure?. Int J Dermatol 47 (2008) 192-194
28. Pomerantz R.G., Husni M.E., Mody E., and Qureshi A.A. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol 157 (2007) 1274-1275
29. Fonder M.A., Cummins D.L., Ehst B.D., Anhalt G.J., and Meyerle J.H. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds 5 (2006) e8
30. Hadziselimovic F. Adalimumab induces and maintains remission in severe, resistant pediatric Crohn disease. J Pediatr Gastroenterol Nutr 46 (2008) 208-211
31. Heffernan M.P., Anadkat M.J., and Smith D.I. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol 143 (2007) 306-308
32. Hubbard V.G., Friedmann A.C., and Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 152 (2005) 1059-1061
33. Woodson J. Use of efalizumab for the successful treatment of chronic recalcitrant pyoderma gangrenosum. Poster presented at: 64th Annual Meeting of the American Academy of Dermatology; March 3-7, 2006; San Francisco, CA.
34. Foss C.E., Clark A.R., Inabinet R., Camacho F., and Jorizzo J.L. An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum. J Eur Acad Dermatol Venereol 22 (2008) 943-949
35. Seishima M., Mizutani Y., Shibuya Y., Nagasawa C., and Aoki T. Efficacy of granulocyte and monocyte adsorption apheresis for three cases of refractory pyoderma gangrenosum. Ther Apher Dial 11 (2007) 177-182
36. Hanai H., Watanabe F., Yamada M., Sato Y., Takeuchi K., Iida T., et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 70 (2004) 36-44
37. Sawada K., Muto T., Shimoyama T., Satomi M., Sawada T., Nagawa H., et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 9 (2003) 307-321
38. Bolognia J., Jorizzo J.L., and Rapini R. Dermatology (2008), Mosby/Elsevier, St Louis (MO)
39. Kiran R.P., O'Brien-Ermlich B., Achkar J.P., Fazio V.W., and Delaney C.P. Management of peristomal pyoderma gangrenosum. Dis Colon Rectum 48 (2005) 1397-1403
40. Ljung T., Staun M., Grove O., Fausa O., Vatn M.H., and Hellstrom P.M. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 37 (2002) 1108-1110
41. Swale V.J., Saha M., Kapur N., Hoffbrand A.V., and Rustin M.H. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab. Clin Exp Dermatol 30 (2005) 134-136
42. Jenne L., Sauter B., Thumann P., Hertl M., and Schuler G. Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumor necrosis factor antibody). Br J Dermatol 150 (2004) 380-382
43. Singh M., Andrew S.M., and Lear J.T. Infliximab as a treatment for recalcitrant pyoderma gangrenosum. Clin Exp Dermatol 29 (2004) 196-197
44. Kaufman I., Caspi D., Yeshurun D., Dotan I., Yaron M., and Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int 25 (2005) 406-410
45. Rispo A., Scarpa R., Di G.E., Cozzolino A., Lembo G., Atteno M., et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 34 (2005) 387-391
46. Stichweh D.S., Punaro M., and Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol 22 (2005) 262-265
47. Adisen E., Oztas M., and Gurer M.A. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy?. Dermatology 216 (2008) 163-165
48. Juillerat P., Christen-Zach S., Troillet F.X., Gallot-Lavallee S., Pannizzon R.G., and Michetti P. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis: case report and literature review. Dermatology 215 (2007) 245-251
49. Sapienza M.S., Cohen S., and Dimarino A.J. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci 49 (2004) 1454-1457
50. Ferkolj I., Hocevar A., Golouh R., and Dolenc V.M. Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease. Acta Dermatovenerol Alp Panonica Adriat 15 (2006) 173-177
51. Kouklakis G., Moschos J., Leontiadis G.I., Kadis S., Mpoumponaris A., Molyvas E., et al. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease: a case report. Rom J Gastroenterol 14 (2005) 401-403
52. Cocco A., Angelucci E., Viscido A., and Caprilli R. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases. Inflamm Bowel Dis 13 (2007) 1317-1319
53. Hewitt D., and Tait C. Use of infliximab in pyoderma gangrenosum. Australas J Dermatol 48 (2007) 95-98
54. Regueiro M., Valentine J., Plevy S., Fleisher M.R., and Lichtenstein G.R. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 98 (2003) 1821-1826
55. Uthman I., El-Sayad J., and Sharara A. Successful treatment of recalcitrant pyoderma gangrenosum with infliximab complicated by tuberculosis despite negative screening tests. Clin Exp Dermatol 30 (2005) 294
56. Lopez San R.A., Bermejo F., Aldanondo I., Carrera E., Boixeda D., and Munoz Z.E. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab. Rev Esp Enferm Dig 96 (2004) 420-422
57. Kugathasan S., Miranda A., Nocton J., Drolet B.A., Raasch C., and Binion D.G. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 37 (2003) 150-154
58. Mimouni D., Anhalt G.J., Kouba D.J., and Nousari H.C. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 148 (2003) 813-816
59. Grange F., Djilali-Bouzina F., Weiss A.M., Polette A., and Guillaume J.C. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. Dermatology 205 (2002) 278-280
60. Triantafillidis J.K., Cheracakis P., Sklavaina M., and Apostolopoulou K. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol 37 (2002) 863-865
61. Romero-Gomez M., and Sanchez-Munoz D. Infliximab induces remission of pyoderma gangrenosum. Eur J Gastroenterol Hepatol 14 (2002) 907
62. Batres L.A., Mamula P., and Baldassano R.N. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr 34 (2002) 558-560
63. Chow R.K., and Ho V.C. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 34 (1996) 1047-1060